Paul Mussenden

Paul Mussenden is the current Chief Executive Officer (CEO) at Cydar Medical, a position he holds with extensive experience in the life science and health-tech industries.1 As a seasoned executive, Mussenden brings a wealth of knowledge to his role, particularly in areas such as corporate strategy, regulatory affairs, IP strategy, business development, and fundraising.

Career Highlights

Previous Roles::

• Non-executive Deputy Chairman and Chair of Audit & Risk Management Committee at LifeArc Limited (June 2014 to December 2021)1
• General Counsel, Company Secretary & Head of Strategic Affairs at BTG plc (August 2000 to August 2019)1
• Equity Markets Advisor at London Stock Exchange
• Associate at Norton Rose Group

Current Positions::

• CEO at Cydar Medical1
• Non-executive director at DRI Healthcare Trust and LifeArc

Achievements and Expertise

At BTG plc, Mussenden played a crucial role in the company's growth, overseeing:

• Merger and acquisition activities
• The company's sale to Boston Scientific for $4.2 billion
• Management of the group IP licensing business, which generated approximately $1 billion in royalty income over 6 years
• Leadership of a small innovative medical device business unit1

Leadership at Cydar Medical

As CEO of Cydar Medical, Mussenden is focused on:

• Developing and championing innovative therapeutics and diagnostics
• Driving the company's efforts to make a greater impact on patient care through cutting-edge research and development1

Mussenden's leadership team at Cydar Medical includes:

• Helen Rae - CFO
• Graeme Penney - Chief Scientific Officer & Co-Founder
• Rob Hague - CTO1

Paul Mussenden's diverse background in legal affairs, financial markets, and healthcare, combined with his strategic vision, positions him well to lead Cydar Medical in its mission to transform the industry through innovative solutions.2